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ABSTRACT, KEYWORDS AND JEL CODES 
The purpose of this research is to develop a greater understanding of the 
internationalisation strategies followed by the companies operating in the pharmaceutical 
sector. This study reviewed and applied a range of relevant literature that was used to 
develop the research questions and hypotheses that were then empirically tested by the 
analysis of a questionnaire made to pharmaceutical companies.  
The analysis focused on the different behaviours and drivers of the companies in their 
internationalisation strategies. And the main results are:  
• Companies follow distinct entry mode for different countries and regions. 
• Among the traditional theories, the OLI paradigm is the model that better 
explains the internationalisation of the pharmaceutical companies. 
• On their decision of where to internationalise the companies tend to go to 
markets where they have established networks. 
• During the last financial crisis (2008 – 2013) the companies took the decision 
to internationalise or increase the degree of internationalisation. 
KEYWORDS: pharmaceutical industry; internationalisation strategy; international 
business administration 
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INTERNATIONALISATION STRATEGIES: A SECTOR ANALYSIS OF THE 
PHARMACEUTICAL INDUSTRY  
By João M. G. Ribeiro 
The purpose of this research is to develop a greater understanding of the 
internationalisation strategies followed by the enterprises operating in the 
pharmaceutical sector. The study reviewed and applied a range of relevant 
literature that was used to develop the research questions and hypotheses, 
which were then empirically tested by the analysis of a questionnaire made to 
companies.  
1. INTRODUCTION 
Globalisation is widely seen as a dominating phenomenon of the 21st century, 
encompassing worldwide integration of financial systems, trade liberalisation, 
deregulation and market opening, resulting in a global market and patterns of industrial 
development. Traditionally, theories relating to the internationalisation of firms have been 
focused on different manufacturing industries. However, due to strict regulations and very 
differentiated factors, there are some general characteristics of the pharmaceutical 
industry that influence the internationalisation process and, therefore, create different 
trends when compared with others. This study analyses the structure of the sector and the 
different types of international decisions made by pharmaceutical companies in Portugal 
and then applies traditional and contemporaneous internationalisation theories to 
determine whether they are appropriate for explaining the recent trends. 
Portugal is a small country and therefore the internationalisation of domestic 
companies and channels for exports are essential to guarantee the long-term success of 
her economy. When became a member of the European Union in 1986, the export profile 
of Portugal was mainly driven by intensive cheap labour. During the following years there 
has been a lack of capability from the country’s enterprises to revert the situation, which 
resulted in a loss of competitiveness and market share with the entrance of players such 
as China (when joined the World Trade Organisation) or the Eastern European countries 
with the enlargement of the European Union. This is considered one of the main reasons 
why Portugal was one of the most affected countries by the Great Recession. Since 2008, 
the profile of the Portuguese companies has changed and the country managed to regain 
some of its competitiveness. This improvement is shown by the performance of exports 
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representing now more than 40% of the gross domestic product, which is a very 
significant growth from the 27% it represented in 2008 (OCDE, 2017). 
The pharmaceutical industry played some role in this recovery. In fact, in the period 
mentioned above, the exports of pharmaceutical products increased from around 400 
million euros in 2008, which represented approximately 1.07% of the total exports, to 
more than 1,000 million euros in 2016, representing approximately 2.13% of the total 
exports (TABLE 1). This shows the weight gained by the sector in the Portuguese economy. 
Nowadays, the Portuguese pharmaceutical sector is considered as highly competitive and 
flexible and the medicines produced in Portugal are exported to more than 100 countries, 
with the most important partners being countries with very high health standards in the 
field such as the USA, Germany and the United Kingdom (AICEP, 2018). 
 
In order to analyse the internationalisation strategies followed by the Portuguese 
pharmaceutical companies, a quantitative research design was chosen, which included a 
survey to the companies with production activity in Portugal (excluding the firms limited 
to R&D or import/export). This focus allowed to better understand the internationalisation 
strategies and explain the drivers for the decision of “if”, “how” and “where to” 
internationalise. 

















2016 50,038.84           1,066.72             636.19                430.53                
2015 49,634.00           846.48                464.93                381.55                
2014 48,053.70           822.56                470.86                351.69                
2013 47,302.91           682.26                450.55                231.71                
2012 45,213.02           664.23                436.11                228.12                
2011 42,828.03           577.04                403.92                173.12                
2010 37,267.91           470.01                341.12                128.89                
2009 31,696.76           457.07                336.47                120.60                
2008 38,847.35           416.92                307.55                109.37                
2007 38,294.06           393.85                293.41                100.44                
2006 35,640.47           338.78                253.23                85.55                  
2005 31,137.08           298.66                220.19                78.48                  
Last update on the data: February 8th, 2018
Year
Exports (Euros) of Pharmaceutical products in Portugal 
Source: Instituto Nacional de Estatística, the National Statistical Institute of Portugal 
extracted from http://www.ine.pt in August 18th 2018 
 
JOÃO M. G. RIBEIRO   
INTERNATIONALISATION STRATEGIES: A SECTOR 




Following this introduction, this paper provides a review of the research that was 
made on the internationalisation of the pharmaceutical companies, as well as it explores 
the singularities of the pharmaceutical sector, in order to explain why it study in light of 
the international theories is relevant. The succeeding chapters include a short literature 
review with the objective of providing a theoretical background on both the classic and 
contemporaneous internationalisation theories and a brief overview of the economic 
structure of the Portuguese pharmaceutical industry. And then, they are followed by a 
chapter including the definition of the research questions and the hypotheses that will be 
tested. 
The section ‘‘research method’’ describes the methodology that was used in addition 
to the data collection procedures and steps that were made to analyse the data. In the 
section ‘‘analysis and discussion of results’’ the findings are presented as well as a 
deliberation about the confirmation or disproval of the hypotheses. Finally, the last 
section concludes with some contributions and limitations of the study, and presents 
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2. INTERNATIONALISATION OF COMPANIES IN THE PHARMACEUTICAL INDUSTRY 
This chapter will explore the specificities of the pharmaceutical industry in the context 
of the internationalisation and provide a review of the work that has been done on the 
subject.  
2.1. Specificities of the pharmaceutical industry 
The pharmaceutical industry is defined as the group of companies that discover, 
develop and produce pharmaceutical drugs for medication use. It includes both generic 
and branded medicines, as well as the non-prescription drugs commonly known as over-
the-counter products (Mcguire et al., 2012). The pharmaceutical industry is very 
important to the population, as one of the drivers supporting the increased longevity, 
ability to work and to improve the quality of life (Lichtenberg, 2015). Apart from that, it 
also plays a role in the worldwide economy with spending on medicines around the world, 
reaching nearly 0.95 billion euros in 2016 and expecting to grow to 1.3 billion euros in 
2021 (QuintilesIMS, 2016). 
Given the ethical requirements and the significant effects on health, medicines cannot 
be seen as normal consumer products. At the same time, manufacturing and development 
of pharmaceutical products require special knowledge and expertise. Therefore, the 
companies operating in the field are in general subject to a variety of specific laws and 
regulations that govern patenting, testing, safety, efficacy and marketing of drugs.  
One of the first steps towards the increasing legislation of the sector was made in 1540 
when the “Apothecaries Wares, Drugs and Stuffs Act” was applied in England, (Rägo 
and Santoso, 2008). Another important event was the creation of the World Health 
Organisation on 7th of April 1948, which nowadays still has a relevant role in the 
development and application of internationally recognised norms, standards and 
guidelines.  
However, it was mainly due to the “thalidomide tragedy”, which was revealed in 
1962, that the current standards of safety were implemented. In fact, this tragedy has 
transformed a drug sold as over-the-counter (claimed to cure anxiety, insomnia, gastritis, 
and tension) into a tragedy, with enormous proportions due to its harmful effects by 
causing malformation of the limbs in newborns. Due to this tragedy, the drug became a 
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symbol of regulations, as it is considered to be the real starting point for the application 
of the concepts of safety and pharmacovigilance for medications (Moro, 2017).  
Nowadays, before a drug can be sold in a country, it must be registered and approved 
by the national competent regulatory authority, in a process also known as “marketing 
authorisation”. This includes the evaluation of the scientific information (called the 
registration dossier) and, in some cases, it includes an inspection to the manufacturing 
facilities, clinical trials, analytical and laboratory analysis, among others. The objective 
is to guarantee to national regulatory agencies that all products which can be used by the 
population (whether prescribed by health professionals or used as self-medication) meet 
the criteria of safety, efficacy and quality (Rägo and Santoso, 2008). It is important to 
refer that, without a specific proof of the previous requirements, a medicinal drug can 
easily cause significant damage to the human health.  
The regulations of the sector are usually very strict and variable from country to 
country. It can include different requirements, such as plant approval, stability tests in 
different temperatures and humidity, format of the dossier, experiences to show the 
effectiveness of the products in animals and humans, among others (Badjatya, 2013). In 
fact, even within the European Union, where most of the procedures are mutually 
recognised among the countries, the approval of medicines is still pretty much dependent 
on national regulatory authorities. These requirements make the pharmaceutical market 
very unique and special, which imposes new challenges and different strategic thinking 
towards the internationalisation for all companies who wants to operate on this field.  
In that sense, the internationalisation in the pharmaceutical sector is considered a very 
complex, expensive and above all, highly time-consuming process. Normally, from the 
first contact and negotiation until the time the first product enters a foreign market it takes 
more than two years (Tomás and Crespo, 2017). The timelines for the process are not 
fixed and vary from one country to the other. Just looking at registration, it can take 
around 6 to 7 months to get an approval in the USA or Europe, but it may take around 1.5 
years in Japan (Thambavita et al., 2018) or 5 years in South Africa (Keyter et al., 2018). 
2.2. The internationalisation in the pharmaceutical industry 
The study of the internationalisation strategies followed by the pharmaceutical 
industry is rather scarce. The work that has been done in the past was focused on sectorial 
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or country-based analysis, not specific to the pharmaceutical sector. The few researches 
that were done especially on this sector are mentioned on this chapter. 
The first study to explore the internationalisation in the pharmaceutical industry was 
published in 1996 and explored with great detail the process of internationalisation of 
Upjohn (later merged with Pharmacia in 1995 and then acquired by Pfizer in 2002) (Fina 
and Rugman, 1996). It is an interesting study as it concluded that the process of 
internationalisation was made in line with the Uppsala model, since it followed a 
sequential process. A few years later a longitudinal study covering the process of 
internationalisation of ten companies (eight pharmaceutical companies and two 
companies of scientific instruments) was performed by Peter and Malcolm (1998). From 
these ten companies, five were separated by the group as their internationalisation 
strategies were influenced by turbulence in the industry, namely mergers or acquisitions. 
It is interesting to find that the study of the internationalisation was not one of the goals 
of the study, but it was published as the research in this area was almost inexistent at the 
time. 
The main difference between the studies mentioned above is the type of companies 
that were studied. While Fina and Rugman (1996) limited their study to one of the biggest 
corporations worldwide, Peter and Malcolm (1998) studied several smaller companies. 
The results were completely different, as while the first identified a sequential process in 
the internationalisation of Upjhon, the second present a very random scenario, in which 
the companies that were monitored during the three years pursued their own 
internationalisation strategies without following a clear stepwise or stage process. In the 
majority of the corporations, the author even noted that the internationalisation was 
followed independently from the global strategy of company. And in some cases, it was 
even pursued in parallel with other strategies, treated as a business project and not being 
consider as a target of the company. The study also highlights the huge impact that the 
mergers and acquisitions had in the definition of the internationalisation process. This is 
particularly relevant, since these activities are very common among the pharmaceutical 
sector, being considered one the most actives at this level among all the industries in the 
world. In fact, the ten biggest pharmaceutical companies account for 20% of the sales in 
1985 and the value increased to 48% in 2002. With much of this growth being the result 
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of mergers and acquisitions that exceeded 500 billion US dollars between 1988 and 2000 
(Çikhoroz et al., 2016; Kumar, 2012).  
During the decade of 2000s, the research on internationalisation strategies in this 
sector was relatively scarce. There were only two papers published and both focused on 
very specific situations without including an analysis of the global strategy or theories. 
The first one studied the entry modes of the pharmaceutical companies. It is an interesting 
paper as it defined a conceptual framework for international pharmaceutical market entry 
and market analysis (Javalgi and Wright, 2003). The second one reviewed specifically 
the decision of why and how the companies would enter the USA market (Howell, 2004).  
Still in this decade, it was published by Dunning and Lundan the 2nd edition of the 
book Multinational Enterprises and the Global Economy (Dunning and Lundan, 2008). 
Although this work was not restricted to the pharmaceutical industry, it is worthwhile to 
mention as it had several conclusions that are applicable to it (or shared with other 
technology and/or capital-intensive sectors). In particular, there are two ideas that are 
relevant to this research. The first is that the tariffs were an important trigger leading to 
foreign investment by pharmaceutical multinationals and one of the major precedents of 
the emergence and maturing of international production in the sector. Nonetheless, the 
authors also refer that nowadays the different stages of the production process are 
normally located across different countries (so-called global value chains) and so the 
tariffs and barriers may block the companies from investing in manufacturing sites in 
countries where they will have restriction on the import of raw materials or intermediates. 
The second interesting conclusion is that pharmaceutical multinational companies invest 
in markets as a part of the global or marketing strategy to have a physical presence in the 
leading markets served by their competitors. 
During the last decade, the research on this area has also been small, with one study 
performed in 2010, having the objective of identifying the motives and patterns adopted 
by five Indian pharmaceutical companies (Kale, 2010). Despite its interest, the study has 
a big limitation, which is to be confined to a handful of very large corporations that 
managed to become big multinationals. The study ends up concluding that the 
internationalisation of the companies that took part on the research was mainly driven by 
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the need to improve global competitiveness. And that the strategy was mainly achieved 
by mergers and acquisitions in Europe, and organic growth in the USA.  
Probably the more important research in this sector was published in 2012. Although 
it was very specific, it provided interesting insights about the relation between the choice 
of market and entry modes in transition economies (Wrona and Trapczyński, 2012). The 
biggest limitation of the study lies on its geographical focus on transition economies (such 
as Eastern European and Southeast Asian). Nonetheless, the conclusions are very 
interesting and the patterns found were several times replicated. The most important 
finding from this study was that the choice of entry and expansion mode were dependent 
on the perceived ratio between market potential and risk factors, which represents a new 
approach to internationalisation. The study compares the findings and establish the 
differences to the OLI paradigm and the Uppsala Model (both explained below) and 
defines the risk-potential ratio as the major driver for the definition of the operating mode. 
The study postulated three interesting conclusions: 
• the more differentiated the products in the portfolio, the higher the confidence 
to command high market potential; meaning that the influence of this 
risk/potential ration is smaller in differentiated portfolios; 
• the higher the prior experience with operations in transition economies, the 
lower the level of perceived risk;  
• the higher the cultural proximity to transition economies, the lower the level 
of perceived risk. 
In 2017, the more recent analysis of the internationalisation of the pharmaceutical 
industry was published (Pereira and Gomes, 2017). It was a qualitative analysis that 
reviewed the internationalisation, followed by four large Brazilian companies. The 
conclusions of the study are interesting as the authors managed to explain the 
internationalisation process followed by all companies based on the traditional theories, 
namely the eclectic paradigm and Uppsala model.   
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3. INTERNATIONALISATION THEORIES 
The current chapter explores the most relevant internationalisation theories, in order 
to create the basis for the analysis of the data collected by means of the questionnaire. 
3.1. Classical theories: the economic and behavioural approach 
In general, the internationalisation theories study “why”, “how” and “where” firms 
internationalise. There are several theories that tried to explain this process and from a 
classical point of view they can be broadly divided into two streams, the behavioural 
approach and the economic approach.  
The behavioural approach is focused on the firm’s decisions that lead to 
internationalisation. The main theory under this stream is the Uppsala Model, which is 
also one of the most important theories explaining the internationalisation process of 
firms. The theory was developed by Swedish authors, who observed that the companies 
usually started operating in nearby markets and only gradually entering into far away 
markets (either geographically or culturally). They also noted that the companies usually 
started by entering new markets through exports and only evolved to wholly-owned 
operations after several years of exporting to the markets, defending that the 
internationalisation of a firm would develop on a stepwise basis (Johanson and Vahlne, 
1977; Johanson and Wiedersheim-Paul, 1975). The Uppsala model presents then the 
internationalisation as a gradual process. It considers that the companies will follow a 
normal process of internationalisation by stages (FIGURE 1). And, although it does not 
need to necessarily go through all steps mentioned in the figure, it will follow some kind 
of flow. It means that the internationalisation decision is made based on a behavioural 
approach, since the first markets where the companies would internationalise to are those 
which are more similar to the domestic one. The objective would be to prioritize the 
countries where the companies have a higher degree of knowledge.  
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These theories are very much associated with the Nordic school, as it was developed 
based on the empirical findings, taking the example of several companies in the Nordic 
countries such as Sweden and Norway. It is important to refer that the theory was never 
consensual, however it is commonly seen as very relevant, especially to explain the first 
stages of the internationalisation process.  
From a general perspective, the behavioural approach is linked to a certain level of 
path or stepwise internationalisation process in which the companies have a rational 
approach, both in terms of location and operating mode as according to the theory these 
would lead to a better knowledge of the foreign markets. Based on the Uppsala model 
other theories were born during the last years, one of the most relevant is the network 
theory, which is further explored in the next chapter. 
Another explanation for the internationalisation is presented by the economic 
approach. These theories focus on the macro environment in which the company is 
inserted or where the company will be aiming to enter. There are several theories that 
follow this idea, and one of the first economists to discuss this was Stephen Hymer  that 
considered that ownership or competitive advantages constitute themselves an incentive 
for international expansion of the companies (Hymer, 1960). Another theory following 
the economic approach is the International Product Life Cycle Model (IPLC Model) 
defending that the entry into new markets depend on the stage of the traded products. It 
also sustains that the companies should enter in less developed markets, taking advantage 
of the advanced stages of lifecycle of its products in the native market (Vernon, 1996).  
However, the main relevant theory that follows this approach is called as the eclectic 
paradigm and it was mainly developed by John Dunning (Dunning, 2001). This author 
did not agree with the theories postulated by the Nordic school and tried to find an eclectic 
explanation that could describe the causality of single cases. This theory is also called as 
FIGURE 1 - Regular sequence of internationalisation of the companies, adapted 
from (Silva, 2002) 
Domestic 
market












Licensing out of 
technologies
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OLI paradigm of international production, due to the fact that it considers three main 
causes for internationalisation (ownership, location and internalisation) and from the 
combination of all of them would result the decision of the company to internationalise, 
and if so, how and to where. A small description of each of the “advantages” is important 
to help to understand the theory: 
o Ownership advantages – refer to advantages that the international 
companies have against local domestic enterprises, which give them a competitive 
advantage. These advantages are mainly due to the ownership of specific resources 
(human resources, technology, brands, and others). 
o Locational advantages – this is referring to advantages the company have 
by being present in a certain foreign country. It can be access to some resources that 
the destination country has, material, natural (mineral, metal, fuel, among others) and 
also human resources. Another relevant factor is the production costs, which may be 
lower in the new country or even the access to other markets.   
o Internalisation advantages – the companies are more interested in doing 
business in their own group and subsidiaries, and they only develop partnerships with 
third parties when that is clearly advantageous. This is also due to market uncertainty 
and the high transaction costs.  
3.2. Contemporaneous internationalisation theories 
Apart from classic models described above, there are a few “new” theories that are 
relevant to this paper. The majority of them could be seen as behavioural approaches. 
However, none of them is purely behavioural or economic.  
One of the theories explain how small firms (mainly the ones created after 2000’s) 
have quickly internationalised without the time or need to develop any firm-specific 
advantage in home markets. These companies have characteristics, such as a global 
mindset, proactiveness, innovativeness and risk taking, and are called “born global”. 
Having far less resources than large firms, they take advantage from having a very 
significant knowledge, which is the result of learning derived from abroad and availability 
to create alliance network relationships (Contractor, 2007; Sullivan Mort and 
Weerawardena, 2006). Another relevant theory was the network theory, which was 
mentioned before. This model highlights the importance that business relationships (both 
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informal and formal) have on the internationalisation of firms (Cunningham and Culligan, 
1988). The markets are perceived as a mixture of relationships between several players, 
including customers, suppliers, producers, competitors, private and public support 
agencies. And it is assumed that the strategy for internationalisation is many times 
dependent on the relationships that the firms are capable to develop with others. In that 
sense, the decision of the firm regarding the entry mode (and even the choice of markets) 
is influenced by their networks of partners and the entry mode may even be the result of 
initiatives taken by a partner.  
Another interesting theory is the “strategic choice framework”. This theory was 
developed on top of the Uppsala model, but with a much more pragmatic approach, 
assuming that companies take into account a big number of factors when deciding to 
internationalise. This is a more flexible model that considers the full range of foreign 
market servicing options available to firms. It also argues that companies do not follow a 
unidirectional pathway, but rather focus on evaluating the cost and profit potential of each 
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4. THE RESEARCH QUESTIONS AND HYPOTHESES 
The theoretical revision from the previous chapter was used to draw a number of 
research questions (RQ) and hypotheses (H) in order to provide a direction to our 
research. The first question is based on the internationalisation strategy and, considering 
the knowledge of the market (and the several companies that develop their activities in 
different regions), it is proposed to confirm if the destination of internationalisation would 
be associated to entry mode.  
RQ1. Do companies follow or associate a different entry mode for different 
regions/countries? H1. The companies will follow or associate different entry 
modes for different regions.  
Considering that the OLI paradigm (Dunning, 2001) is one of the most important 
theories following the economic approach, this research tried to confirm if this theory 
could be helpful in explaining the decision to internationalise of the pharmaceutical 
companies.  
RQ2. Can the internationalisation process followed by the companies be 
explained based on the OLI paradigm? (Dunning, 2001). H2. The companies will 
follow a strategy in line with the OLI paradigm. 
Considering that the Uppsala model (Johanson and Vahlne, 1977; Johanson and 
Wiedersheim-Paul, 1975) is one of the most important theories following the behavioural 
approach, this study tried to confirm if this theory could be helpful in explaining the 
decision to internationalise of the pharmaceutical companies. 
RQ3. Can the internationalisation process followed by the companies be 
explained based on the Uppsala model (Johanson and Vahlne, 1977; Johanson and 
Wiedersheim-Paul, 1975)? H3. The companies will follow a strategy in line with 
the Uppsala model. 
The pharmaceutical sector requires a high level of knowledge (due to the strict 
regulations and requirements). This led to consider the hypothesis that the companies 
would rely on their network connections in order to reduce the risk of their decisions, in 
particular the choice of where to internationalise, in line with the network theory 
(Cunningham and Culligan, 1988).  
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RQ4. Do the companies tend to internationalise to markets where they have 
networking connections? H4. The companies will tend to internationalise to 
markets where they have established networks. 
Portugal was one of the most affected countries by the global financial crisis in the 
end of the decade of 2000s. This creates the perfect scenario to study how the companies 
reacted to this economic downturn and how was their internationalisation strategy 
affected by it. Moreover, apart from the changes in the internal market, the after-crisis 
period lead to several changes on the Portuguese companies, namely the export profile 
(OCDE, 2017). So, it is relevant to understand how did the Great Recession affected the 
decision of the companies towards the internationalisation. 
RQ5. Do the companies decide to internationalise when they are exposed to crisis 
environment? H5. The companies have taken the decision to internationalise (or 
increase the degree of internationalisation) during the crisis period. 
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5. THE ECONOMIC STRUCTURE OF THE PORTUGUESE PHARMACEUTICAL INDUSTRY AND 
EVOLUTION OVER THE LAST TWENTY YEARS 
The first steps towards development of the Portuguese pharmaceutical industry date 
back to 1891, with the foundation of the first pharmaceutical company. However, it was 
only in the middle of 20th century that the sector had a significant growth, with the creation 
of new regulations and establishment of production units by multinational companies. 
Later, in the end of 20th century, the pharmaceutical industry went through a difficult 
period related with the Portuguese membership of the European Economic Community 
due to a reduction of trade barriers, which resulted in the divestment of multinationals 
from the production units they had previously established (Apifarma, 2014).  
In the 21st century, the sector underwent several changes driven by the growth of 
established companies and creation of new ones. An important difference in this new era 
is that, apart from the multinational companies, the local companies started looking at the 
international market as an opportunity to grow. And the exports of the sector increased a 
lot as it will be showed below. This new perspective gives the perfect background to 
identify the drivers that lead to the decisions of “if”, “how” and “where to” 
internationalise. 
Before starting the description of the structure of the Portuguese pharmaceutical 
industry, it is important to define it. The “pharmaceutical companies” are considered as 
enterprises registered with principal economic activity code as the manufacturing of 
pharmaceutical base products (211) and the manufacturing of pharmaceutical finished 
products, which includes medicines and other pharmaceutical products (21201 and 
21202). As for the product-basis analysis, “pharmaceutical products” were considered as 
products classified in the combined nomenclature as medicines (3003 and 3004) and other 
pharmaceutical products (3001, 3002, 3005 and 3006). The full details of the economic 
activity code and combined nomenclature is provided in Appendix I. 
The sector has 141 companies with 6,752 employees, representing around 0.01% of 
the total number of companies in Portugal. However, the population employed in the 
sector represents around 0.18% of the total population employed (TABLE 2). The small 
number of companies (compared with other sectors) may be explained by the barriers, 
namely high regulations. The pharmaceutical industry is a very high value-added sector 
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and much more productive compared with the average. With a relatively low consumption 
of resources, it fairly contributes to the country’s economic prosperity. Based on the 
number of employees, the pharmaceutical companies have on average 47.8 employees, 
while the total sectors in Portugal have only 3.1. As for the value added, in 2016, each 
pharmaceutical company had on average a value added of 3.2 million euros, which is 44 
times higher than the average.  
 
According to the definition of the European Commission, the companies can be 
divided into micro, small, medium-sized and large enterprises. The category of micro, 
small and medium-sized enterprises (SME) is made up of companies which employ fewer 
than 250 persons and which have an annual turnover not exceeding 50 million euro, 
and/or an annual balance sheet total not exceeding 43 million euro. Within the SME 
category, a small enterprise is defined as an enterprise which employs fewer than 50 
persons and whose annual turnover and/or annual balance sheet total does not exceed 10 
million euro. And a microenterprise is defined as an enterprise which employs fewer than 
10 persons and whose annual turnover and/or annual balance sheet total does not exceed 
2 million euro (European Comission, 2003). Following this definition, from the total 
number of companies, 110 are micro and small enterprises, 78% of the total, but that are 
TABLE 2 - Characterisation of the Portuguese pharmaceutical industry sector  
Total 1,196,102     3,704,740  48,922           226,659          85,410             
Pharmceutical Ind. 141               6,752         217                1,065              441                  
Total 1,163,082     3,578,913  46,890           220,338          80,548             
Pharmceutical Ind. 134               6,302         203                1,064              444                  
Total 1,128,258     3,449,428  44,800           215,478          76,131             
Pharmceutical Ind. 131               6,243         200                971                 398                  
Total 1,098,409     * 3,377,598  * 43,923           * 212,977          * 73,111             *
Pharmceutical Ind. 127               6,089         190                1,028              413                  
Total 1,065,173     * 3,405,269  * 44,872           * 217,166          * 73,126             *
Pharmceutical Ind. 122               6,098         191                1,107              388                  
Total 1,113,559     * 3,631,747  * 48,136           * 232,478          * 79,339             *
Pharmceutical Ind. 126               6,076         203                1,012              339                  
Total 1,145,390     * 3,732,512  * 49,230           * 236,294          * 84,956             *
Pharmceutical Ind. 127               6,084         211                1,025              364                  
Total 1,199,843     3,834,544  48,709           225,792          84,227             
Pharmceutical Ind. 130               5,958         195                990                 381                  
Total 1,235,989     ┴ 3,961,546  ┴ 49,248           ┴ 248,939          ┴ 88,037             ┴
Pharmceutical Ind. 135               ┴ 5,974         ┴ 200                ┴ 970                 ┴ 402                  ┴
Legend of symbols:
*: Rectified data
┴: Break in the series/comparability



























Source: Instituto Nacional de Estatística, the National Statistical Institute of Portugal extracted 
from http://www.ine.pt in August 8th 2018 
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responsible for only 5% of the total production value. 24 are medium-sized enterprises 
and represent around 43% of the total production value of this sector. And finally, there 
are 7 large enterprises (5% of the total), which represent a total production of more than 
500 million euros (around 52% of the total sector). Since 2010 the number of companies 
have been growing (11% increase between 2010 and 2016) with the micro companies 
being the ones that grew more in number (without an increase in the production value). 
The biggest increase in the production value happened among the large enterprises (which 
increased around 60% growth from 2010 to 2016). All the data referred to in this last 
paragraph can be observed in TABLE 3. 
 
In terms of the Portuguese economy, the pharmaceutical industry holds a raising 
position (see TABLE 2, above). Although it represents only 0.18% of the total employed 
population, it accounts 0.44% of the total wages paid in Portugal (an increase from 0.41% 
in 2008). It is responsible for 0.47% of the total production value (an increase from 0.39% 
in 2008) and 0.52% of the gross added value by the Portuguese companies (an increase 
from 0.46% in 2008). Furthermore, the sector represents more than 2% of the total 
exports, which clearly shows its raising importance within the national economy (see 
TABLE 1, Chapter 1).  
The Portuguese pharmaceutical industry is also seen as one of the best performing 
sectors in terms of international activity, particularly exports. The total value of exported 
pharmaceutical products was, in 2016, 1,066 million euros, which represents an increase 
No. 10
6
 euro No. 10
6
 euro No. 10
6
 euro No. 10
6
 euro No. 10
6
 euro
2016 141 1,065       90 19            20 38            24 456          7 553          
2015 134 1,064       86 29            19 46            22 459          7 530          
2014 131 971          77 ... 24 ... 24 472          6 426          
2013 127 1,028       76 ... 20 ... 25 504          6 461          
2012 122 1,107       68 24            22 67            26 538          6 478          
2011 126 1,012       72 32            21 50            28 587          5 344          
Legend of symbols:
...: Confidential data 
Last update on the data: February 8th, 2018
Less than 10Total More than 250Year





TABLE 3 - Characterisation of the Portuguese pharmaceutical industry 
sector by size of the companies and production value 
Source: Instituto Nacional de Estatística, the National Statistical Institute of Portugal 
extracted from http://www.ine.pt in August 18th 2018 
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of more than 257% from 2008. This is even more impressive when compared with other 
Portuguese sectors, since the total exported value increased 61% in the same period. This 
means that, in 2006, 0.95% of the total Portuguese exports were derived from 
pharmaceutical products and this value has grown to more than 2.1% in 2016 (TABLE 1).  
The increase of traded value was relevant in the intra-EU market. However, the 
biggest increase was in the extra-EU trade, which represented, in 2016, 40% of total trade 
value (after achieving a peak of 45% in 2015), a substantial increase from the percentage 
it represented in 2008 (26%). This is a significant contribution to the diversification of 
Portuguese exports insofar as the extra-EU only represent 25% of total exports (FIGURE 
2). 
 
Summing up, the Portuguese pharmaceutical sector is becoming important to the 
Portuguese economy and it seems to be very dynamic, considering the several countries 
to where the companies export to. In that sense, despite being small, the growth that it 
had over the last years, especially on international trade, makes it the perfect sample for 
the study of internationalisation strategies.  
FIGURE 2 - Intra EU exports of goods compared with Extra EU export of goods 
by Member State, 2016 (share %), source: Eurostat, Comext table DS-063319 
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6. RESEARCH METHOD 
The present research was carried out between June 2018 and August 2018. The target 
group was Portuguese companies with principal economic activity code as the 
manufacturing of pharmaceutical base products (211) and finished products, including 
medicines and other products (21201 and 21202) as referred to in the Appendix I. The 
sample was obtained from an online database (https://iberinform.pt/pesquisa.jspx).  
A first screening was done over the total sample to identify companies belonging to 
the same group1. The objective of this step was to avoid sending the questionnaire to the 
same group of companies more than once. Otherwise the answer would be duplicated and 
given the small sample size it would impact the results. The sample was comprised of 
163 companies and 15 were excluded after this initial screening.  
The database was further analysed aiming at removing small and micro companies 
with reduced production activities. This is important as there are several companies which 
are only focused on R&D (including spin-offs from universities) or import and export 
activities that have limited production activities (or do not have at all) and therefore were 
not the target of the study. The methodology defined was to type the name of each 
company in an internet search engine (https://www.google.pt) and all the companies 
which didn’t have any type of internet presence (including website or social media page 
with contact detail) were excluded from the analysis. From this second step 73 entries 
were excluded. Reducing the final sample to 75 companies which were considered as the 
target of the study. In order to further explain the scope of the research, the sample was 
cross-checked with the list of companies that held a Good Manufacturing Practice license 
for the manufacturing of pharmaceutical products, since this permit is essential for the 
companies to manufacture medicines. There are currently 171 licenses in Portugal (each 
manufacturing unit represents one license) belonging to 25 companies involved in the 
manufacturing of medicines. The sample of contacted companies included 20 of those, 
which represent 80% of the total companies with a permit to manufacture pharmaceutical 
products in Portugal.   
                                                 
1 Group of companies meaning parent and subsidiary corporations that function as a single economic 
entity through a common source of control. 
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The method chosen for the research was a quantitative web survey. This gave the 
opportunity to reach more companies than a qualitative approach, namely case-study 
analysis. The objective was to replicate the results for the target group of companies and 
create a general picture of the drivers for the decision of “if”, “how” and “where to” 
internationalise. The survey was designed based on international standards (University of 
Wisconsin, 2010) and it was available in two languages, Portuguese and English (see 
Appendix II and Appendix III). The survey was performed using an online platform 
(https://www.qualtrics.com) and it was optimised for being answered both in desktop, 
tablet or smartphones.  
The questionnaire was sent directly to the CEO, international business development 
managers or export managers whenever it was possible. And all questionnaires which 
were not answered within one month were followed with a reminder also sent by e-mail. 
When a direct e-mail address could not be used, the e-mail was sent to a general address 
at the attention of the international department. The questionnaire was effectively 
(without bounce back) sent to 60 companies. And 14 answers were received, with one 
company mentioning that the economic code was outdated and they no longer had any 
production activity. So, a total of 13 effective replies were received which represents 17% 
of the total sample of companies with principal economic activity code as 211, 21201 and 
21202 (Appendix I) and 44% of all the companies with a Good Manufacturing Practice 
license for the manufacturing of pharmaceutical products. 
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7. ANALYSIS AND DISCUSSION OF RESULTS 
The purpose of this chapter is to report findings and analyse the data based on the 
review of the literature along with observations and the conceptual framework provided 
in Chapter 3.  
7.1. Background information of the respondents 
The core business of the respondents is presented in FIGURE 3. Among the total 
answers, 67% of the companies selected generic medicines. Closely followed by the over-
the-counter medicines, chosen by 42%. The innovative medicines were selected by 33% 
and the fast-moving consumer goods (food supplements, nutraceuticals, medical devices 
and other less regulated products) were selected by 25% of the companies. The cosmetics 
and services were only selected by one company, making it less relevant in the context of 
the analysis. And there were no companies involved in the production of veterinary 
products, medicinal gases and active pharmaceutical ingredients or raw materials. 
 
In terms of the year of creation, not all companies provided the information (since it 
was optional on the survey). Moreover, given the small sample size, it was needed to 
group the answers in order to avoid a possible identification of the respondents. From the 
total respondents, 60% of the companies were founded before 1989, while 20% started 
operations between 1990 and 1999 and 20% between 2000 and 2010.  
The majority of the companies are classified as large enterprises (European 
Comission, 2003). Analysing this parameter in terms of the number of employees (TABLE 
5), 67% of the companies are classified as large companies (with 25% having more than 
FIGURE 3 - Core business of the respondent companies 
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500 employees, and 42% between 251 and 500 employees). The percentage of medium-
sized companies is 25% and the remaining 8% are small or micro companies. Considering 
the turnover (TABLE 4), the numbers would be similar, with 58% of the companies being 
considered large enterprises (33% with a turnover of over 100 million Euros and 25% 
between 51 and 100 million Euros). 33% medium-sized enterprises (25% with a turnover 
between 26 and 50 million Euros, and 8% between 11 and 25 million Euros). And again, 
the remaining 8% falling under the category of micro companies. Making a classification 
of companies based on both parameters would be interesting, however, given the small 
size of the sample, and to protect the identity of the respondents, this was not done.  
                             
It is important to refer that the profile of the companies that answered the 
questionnaire does not match the overall general profile of the companies of the sector 
that can be seen in TABLE 3. In this study, 67% are classified as large enterprises, while 
in the overall sector only 5% of the companies belong to this category. This may have 
three explanations. The first is that the data in TABLE 3 is referring to the official data 
from the Portuguese statistic office and considers each individual fiscal identity a 
different company, while in the study the whole group was considered. So, several of the 
companies that answered the questionnaire are actually comprised by smaller companies 
(under a common source of control).  
The second reason for the overrepresentation of large enterprises is related with the 
small size of the sample. The research was limited to companies having the principal 
economic activity code as manufacturing of pharmaceutical base and finished products, 
which are activities requiring a large scale and high level of capital investment (BAK 
Economics AG, 2017). In that sense, the small and micro companies are probably 
Note: percentages may not total to 100 
percent due to rounding. 
TABLE 4 - Size of the companies 
in turnover 
TABLE 5 - Size of the companies in 
number of employees 
Note: percentages may not total to 100 percent due 
to rounding. 
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unipersonal enterprises (in many cases start-ups focused exclusively on research and 
development activities or import and export business) with reduced production activities 
(some of those without even any kind of website or contact that were excluded during the 
first screening). The third and last reason for this is that probably the bigger companies 
are more likely to have already established international activities and therefore were 
more open to answer the questionnaire.  
Apart from evaluating the size of companies by their turnover and number of 
employees, it is also important to make this analysis regarding the importance that these 
companies have to the domestic market. According to IQVIA data (considered as the 
reference for market data in the sector) the companies that answered the questionnaire 
have in total 27% of the market share (in units) in Portugal2. This number is relevant 
considering that the study only covered the enterprises with production in Portugal, while 
the market has several players (some of those market leaders), which are multinational 
companies only with a commercial presence. In the sample, 5 of the companies are 
included in the top 15 of companies in terms of market share, while the others have 
smaller market share.   
7.2. International activities and operating mode 
All the companies that answered the questionnaire reported to have some kind of 
international activity (see FIGURE 4) and 92% have some degree of internationalisation. 
The licensing out of product/technologies is the most frequent model, selected by 85% of 
the total companies. The import of active pharmaceutical ingredients was mentioned by 
77% and, although it is not considered as an activity contributing towards the 
internationalisation of the company, it is line with the literature review as it shows how 
much the companies of the sector are exposed to the global value chains (Dunning and 
Lundan, 2008). 
The higher degrees of internationalisation, including having a manufacturing site in a 
foreign country or sales facilities outside Portugal, as well as joint ventures and co-
developments, were mentioned by a smaller number of companies. And, although the 
                                                 
2 This market share is related to the total consumption of pharmaceutical products in Portugal and it 
also includes all the imported products. It is different from the percentage referred to in Chapter 5 which 
was related with the total production value. 
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numbers are similar to what has been observed in other sectors (Forsman et al., 2006), it 
is an interesting finding, especially due to the fact that the majority of the companies that 
answered the questionnaire have a large size, which is typically associated with higher 
internationalisation levels. In that sense, there may be some barriers preventing the 
companies from developing their activities in foreign countries particularly when it 
requires foreign direct investment, such as the creation of manufacturing sites. An 
interesting subject for further investigation can be to identify those reasons as it 
contributes to help understanding the internationalisation strategies in this sector. 
 
In terms of the most relevant destination countries of the international activities 
(FIGURE 5), Spain, Germany and Angola appear as the main countries, each one 
mentioned by 45% of the respondents. Regarding the most important country, Angola 
was mentioned by 31% of the companies (followed by Spain, 23%). This shows that the 
proximity may have some influence on the decision of where to internationalise, given 
that Spain is the geographically closest country to Portugal and Angola is an ex-colony 
and therefore culturally and linguistically close. The trends in terms of destination 
countries for internationalisation seems to be in line with what has been found in the past 
for other sectors (Oliveira and Teixeira, 2011). 
 
FIGURE 4 - International activities (by model) that companies report to have 
FIGURE 5 - TOP 5 most important countries for the companies 
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It is clear that there is a pattern between the operating or entry mode and the country 
of destination of internationalisation (TABLE 6). Starting with Angola, a less regulated 
country, 63% of the companies that selected this country aim at the distribution of own 
brands (direct export). While in more regulated markets such as Spain, Germany, the USA 
and the UK, the companies are following very heterogeneous business models. In Spain, 
there is a large number of companies that opened sales office, which may be explained 
by geographical proximity. While in the USA the companies are following models 
requiring a high integration with local companies (through licensing out of technologies, 
co-developments and joint ventures), which is also understandable due to the size and 
complexity of the country, not only from a regulatory perspective, but also in terms of 
market access.  
The questionnaire was also used to 
identify changes on the operation model 
over the time, by asking the companies to 
refer, for their top 2 countries, what was the 
business model followed since their 
entrance on that market and for the 
following years (2000, 2005, 2010, 2015 
and 2017). In the majority of the cases, the 
companies were following the same 
operating mode in 2017 that they did in their 
first year of activity on that country, which 
shows that there was no change over time. 
This is a clear sign that the theories of the 
Uppsala model (Johanson and Vahlne, 
1977; Johanson and Wiedersheim-Paul, 
1975), which postulated the internationalisation as a dynamic and sequential process, are 
not able to explain the entry modes followed by the companies in the pharmaceutical 
sector. These theories indicate that companies would start with a small presence 
(distribution of own brands, meaning direct exports) and would then increase to the 
creation of affiliated companies and manufacturing sites. In the pharmaceutical sector, 
Country International activity Total
Spain Distribution (own brand) 30%
Sales Office 20%
Licensing out of your products/technologies 20%
Manufacturing site 10%
Co-development of products 10%
Other 10%
Germany Licensing out of your products/technologies 33%
Distribution (own brand) 33%
Sales Office 11%
Co-development of products 11%
Joint venture with local company 11%
Angola Distribution (own brand) 63%
Other 13%
Sales Office 13%
Licensing out of your products/technologies 13%
USA Licensing out of your products/technologies 60%
Co-development of products 20%
Joint venture with local company 20%
UK Distribution (own brand) 40%
Licensing out of your products/technologies 40%
Sales Office 20%
TABLE 6 - Kind of international activity per 
country 
Note: percentages may not total to 100 percent due to rounding. 
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this seems not to be the case as the operating mode appears to be associated with the 
region or country and it does not change over time. 
Companies were asked to correlate a business model to different countries or regions 
(TABLE 7), and the result clearly indicates that they associate different entry modes to 
different regions. This may be a sign that the pharmaceutical companies tend to define 
their internationalisation strategy, namely the entry mode, not so much on the stage of the 
company, the products, or their competitive advantages. Rather, they support their 
decision on different factors, which may be related with the potential of the market and 
its specificities, such as complexity, potential and facilities of access.  
 
The less regulated countries, Portuguese speaking African countries, Middle East, 
Africa and Latin America, are associated with direct exports (distribution of own brand), 
while more regulated regions, Europe and the USA, seem to be linked with more complex 
modes, requiring higher integration with the market or the local partners, with licensing 
being the main model associated to these regions. The only exception to this is the Asian 
region, where the licensing is also relevant, even though it has several less regulated 
countries, particularly in the South East. One explanation may be that this is a very 
heterogeneous region with highly regulated markets, such as Japan (which is considered 
a stringent regulatory authority in line with the USA and Europe), while other are less 
regulated markets.  
The time it takes for the companies to start developing their international activities 
has also been studied. On average, companies were operating for 23 years when they 
started their internationalisation process. However, 20% of the companies that answered 
Note: percentages may not total to 100 percent due to rounding. 
TABLE 7 - Operating mode per region 
















90% 33% 33% 13% 80% 0% 50% 14%
Licensing out 0% 33% 0% 63% 10% 100% 38% 86%
Manufacturing site 0% 0% 0% 0% 0% 0% 0% 0%
Joint venture 0% 33% 0% 0% 0% 0% 0% 0%
Sales office 10% 0% 50% 13% 10% 0% 13% 0%
Import from this 
country
0% 0% 17% 13% 0% 0% 0% 0%
Co-development 0% 0% 0% 0% 0% 0% 0% 0%
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the questionnaire started their international activities in the same year of establishment, 
and 40% before achieving 10 years of operation. Another interesting detail is that all 
companies that started the international activities in the same year of foundation were 
created after 2000, which is in line with the theories of the “born global”. 
7.3. Internationalisation drivers 
In terms of the drivers for the decision of “if”, “how” and “where to” internationalise, 
the first subject to clarify was the strategy followed by the companies in terms of the 
countries in which they want to operate. The answer was not conclusive, as 54% of the 
respondents reveal that they concentrate their activities on carefully selected target 
countries, while 46% reveal that they try to do business in as many countries as possible. 
Given the small sample size, the difference is not significant and this probably shows that, 
on this sector, there is neither a clear strategy of market concentration nor market 
diversification. The results are similar to what has been found in other sectors and 
countries (Kymen and Pietilä, 2007). 
Regarding the reasons influencing the decision of companies to internationalise or not 
(TABLE 8), the most relevant was “to explore new markets to grow”. 54% of the 
respondents strongly agreed and 38% agreed that this affected their decision to 
internationalise, which means that the great majority of the companies consider this a 
relevant driver for their decision to internationalise. The reason for this may be the fact 
that, as referred above, the Portuguese market is small and, therefore, the pharmaceutical 
companies try to get scale from the international market, as result of the industry’s high 
capitalisation, workforce with an above-average level of qualifications and a high level 
of production efficiency (BAK Economics AG, 2017). 
 
Note: percentages may not total to 100 percent due to rounding. 













Successful experience from other companies in the internationalization process 15% 23% 31% 31% 0% 0% 0%
To reduce the exposure to the national market 46% 31% 8% 8% 0% 8% 0%
Explore new markets to grow 54% 38% 8% 0% 0% 0% 0%
Governmental measures (inc. national or EU programs) 0% 23% 31% 38% 8% 0% 0%
Contacts received from foreign companies 8% 69% 0% 23% 0% 0% 0%
Reduction of the transaction costs (commissions, taxes, etc.)  0% 8% 15% 54% 8% 15% 0%
Increase the lifecycle of established products in the current markets  15% 38% 8% 31% 8% 0% 0%
Possibility of explore a superior competitive position of rival domestic companies 15% 46% 15% 23% 0% 0% 0%
Take advantage of the location of the destination country 8% 46% 23% 23% 0% 0% 0%
Avoid the knowledge to be shared with third parties (traders, agents, etc.)  0% 8% 31% 46% 0% 15% 0%
Exhibition and networking events 8% 15% 23% 46% 0% 8% 0%
TABLE 8 - Factors influencing the decision to internationalise 
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Another relevant factor was “to reduce the exposure to the national market”, with 
which 77% of the respondents agreed or strongly agreed. This may be related with the 
fact that Portugal was one of the most affected countries during the Great Recession, 
which included mandatory price decreases of the medicines implemented by the 
government. This reduced the profitability of sales in the domestic market and, therefore, 
promoted the internationalisation of the companies that tried to look for new markets in 
order to keep growing. This is further confirmed by the answer to the question on how 
have the financial crisis influenced their willing to internationalise. The same percentage 
(77%) of the respondents revealed that during this period their willing to internationalise 
increased, and only 23% revealed that it did not affect, while no company indicated that 
the crisis negatively affected their decision.  
The answers mentioned in the previous paragraphs are aligned with the findings from 
other researches (Wrona and Trapczyński, 2012) and the new theories of strategic choice 
(Clark and Mallory, 1997), they show that the companies do not have a rationale or step 
approach to internationalisation. Rather, they have a decision based on the potential 
profits that new markets may bring, which can show that they tend to follow a decision 
based on the profit/risk ratio.  
In any case, the results are not totally clear, as topics such as “the possibility of explore 
a superior competitive position of rival domestic companies” and “take advantage of the 
location of the destination country” seem also to contribute to the decision to 
internationalise, but in a smaller degree (TABLE 8). At a certain extent, the traditional 
theories, namely the economic approach (OLI paradigm), may also be able to explain the 
internationalisation process of some companies. This could be a major topic for further 
study as companies with different degrees of internationalisation could potentially follow 
different strategies. 
Also 53% of the respondents agreed or strongly agreed that one of the drivers for 
internationalisation was the increase of the lifecycle of established products in the current 
markets, which may be a validation of the IPLC Model. This theory sustains that 
internationalisation is a process where the entry into new markets will depend on the life 
stage of the traded products, and that the companies should enter in less developed 
markets, taking advantage of the advanced stages in the lifecycle of its products in the 
JOÃO M. G. RIBEIRO   
INTERNATIONALISATION STRATEGIES: A SECTOR 




native markets (Vernon, 1996). Again, it would be interesting to further study how the 
type of products affects the decision to internationalise.  
The companies were also asked to select the three main factors that influenced their 
decision of where to internationalise (TABLE 9). And the established network in the 
country of destination appears as the most relevant factor, selected by 77% of the 
companies. This is a strong indication that the “network theory” may be relevant in the 
context of the pharmaceutical industry and that the strategy for internationalisation in this 
sector is quite often dependent on relationships that the firms are capable of developing 
with other firms in the destination country. One of the reasons for this strong impact of 
the relations between companies may be the long, complex and extensive process for sale 
of a pharmaceutical product in a new country. Consequently, companies focus their 
efforts on markets where they have already identified a partner in which they can trust.  
 
The market size was also one of the main factors selected by companies. This is not 
directly associated with any traditional internationalisation theory, however, in 
combination with regulatory and legal environment (selected by 46% of companies), it 
indicates that the risk/benefit ratio is taken in consideration when selecting the target 
countries for internationalisation, in line with other researches (Clark and Mallory, 1997; 
Wrona and Trapczyński, 2012). 
The similar business culture and language was selected by 31% of the respondents, a 
similar value to what can be observed in the companies that have Spain or Angola as the 
most important country for their international activities (Chapter 7.2). Spain is 
geographically close and Angola is culturally and linguistically close, so the results may 
TABLE 9 - Factors influencing the decision of the destination country of 
internationalisation 
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indicate that, in some stages, the Uppsala Model may also be useful to understand their 
internationalisation process (Johanson and Vahlne, 1977; Johanson and Wiedersheim-
Paul, 1975). It is clear that the process is not gradual in terms of operating mode, but it 
seems that, at least in some cases, the companies prefer to start operating in markets that 
have these characteristics of proximity and gradually start to enter into far away markets. 
The impact that the experience of the senior management had and the possible relation 
with the percentage of international sales of each company were also studied. The results 
were not conclusive, but it seems that there is no correlation between the two parameters. 
7.4. Experiences and perceptions of internationalisation 
It is clear that the pharmaceutical companies that answered the questionnaire 
consider internationalisation as an important part of their business. However, and as 
already detailed in other chapters, competing in international markets is not effortless. 
Therefore, the perception of the companies regarding their experience with 
internationalisation was evaluated in the study.  
As it can be seen from the TABLE 10, the perception of the companies about their past 
experience with internationalisation is very positive, with 62% of the companies referring 
a very positive experience and the remaining 38% showing a positive experience. Similar 
results were also observed on the perspective for the next 3 years (TABLE 11) in which 
just 15% of the companies indicated that the importance of the international activities will 
be kept, while the remaining 85% of companies forecast their increase. Both cases show 
that the perception and experience of the pharmaceutical companies in Portugal towards 
the internationalisation is evaluated as very positive.  






The company does not have any 
experience with internationalisation 0%
What is your perception about the impact of 
the international business activities to your 
company?
TABLE 10 - Perception about the 
impact of international business 
activities in the companies 
Note: percentages may not total to 100 percent due 
to rounding. 
Increases a lot 23%
Increases somewhat 62%
Stays the same 15%
Decreases somewhat 0%
Decreases a lot 0%
In your opinion, what will happen to the 
importance of international business activity 
for your enterprise within the next 3 years?
TABLE 11 - Perception about 
evolution of international business 
activities in the next 3 years 
 
Note: percentages may not total to 100 percent due 
to rounding. 
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7.5. Discussion of the results 
The first question this paper tried to answer was whether the companies follow or 
associate different entry modes to different regions/countries. The results in the TABLE 6 
and TABLE 7 show that H1 is supported as there is a connection between the entry mode 
of the companies and destination. Regions such as Portuguese speaking African and 
Middle Eastern countries (less regulated) are clearly associated with distribution of own 
brands (direct exports), which requires less productive integration with local players. 
While European countries and the USA are more associated with licensing, joint-ventures 
and other models insofar as they require higher degrees of cooperation.  
The second goal was to assess if the traditional models based on an economic 
approach, namely the OLI paradigm, can be used to understand the decisions to 
internationalise followed by the pharmaceutical companies. The H2 seems to be 
confirmed, although results are not conclusive. The main assumptions can be made based 
on the data from TABLE 8, where the possibility of exploring a better competitive position 
of rival domestic companies and taking advantage of the location of the destination 
country contributed to the decision to internationalise. Although these are no main drivers 
for the decision, it supports the fact that the advantages considered in the eclectic 
paradigm (especially ownership and location) are clearly relevant in the context of the 
pharmaceutical industry.  
 The behavioural approach to internationalisation, in particular the Uppsala model, 
seems to apply in a much less extent to the pharmaceutical sector and, therefore, the H3 
is more difficult to prove than otherwise. This theory sustains that the companies usually 
start by operating in new markets through direct exports and then develop on a stepwise 
basis (Johanson and Vahlne, 1977; Johanson and Wiedersheim-Paul, 1975). As it has 
been seen before, the pharmaceutical companies seem to select their operation model 
based on the region/country rather than the stage (H1). Furthermore, most of the 
companies are operating with the same business model over time, a sign that there is not 
a clear rational approach for an internationalisation by stages.  
However, the application of this theory cannot be fully excluded because the authors 
also argue that the companies start by operating in nearby markets and only gradually 
start entering into far away markets. This may be observed in TABLE 9, with 31% of the 
JOÃO M. G. RIBEIRO   
INTERNATIONALISATION STRATEGIES: A SECTOR 




companies revelling that similar business culture and language were important on their 
decision of where to internationalise. And the same may be confirmed by the high 
percentage of companies selecting countries such as Spain or Angola as the most 
important country for their international activities. Although it is clear that the process is 
not gradual in terms of the operating mode, the destination of the internationalisation may 
be explained by the Uppsala model to some extent.  
The results of the TABLE 9 show that the H4 is supported, with 77% of companies 
selecting the existing network in the target country as a driver for their decision regarding 
where to internationalise. This is in line with the “network theory” explored in the Chapter 
3.2. 
The H5 was also supported, given that 77% of the respondents revealed that during 
the financial crisis their willing to internationalise increased and only 23% revealed that 
it didn’t affect their decision (while no companies mentioned that the crisis reduced their 
willing). Also, results from TABLE 8 reveal that 77% of the respondents agree or strongly 
agree that the reduction of exposure to the national market influenced their decision to 




The importance of internationalisation in an increasingly globalised world is apparent 
for all countries and sectors, with Portugal and the pharmaceutical industry being no 
exception. It is clear that the specificities of the sector, namely the strict regulations and 
requirements, make it a very interesting case to be studied in this context. Taking the 
example of the European Union, where the single market is described as one territory 
without internal barriers or other regulatory obstacles to the free movement of goods and 
services, the pharmaceutical sector appears as an exception, where there is always a 
national registration procedure, which can take a long time and is essential for selling 
pharmaceutical products in any country. Furthermore, the quality and safety requirements 
create new challenges for the companies to enter in new markets, which oblige for an 
extensive knowledge.  
This paper has given an overview of the internationalisation process, focusing on the 
strategies followed by the pharmaceutical companies in Portugal. The results of the 
quantitative study support the majority of hypotheses developed by the author. In several 
cases, the internationalisation decision of the companies cannot be explained by a single 
internationalisation theory, but rather a combination of all.  
8.1. Limitations of the study and need for further research 
Like any other empirical research, this study is confronted with limitations. Due to 
the quantitative character of the study, it is affected by a restriction faced also in other 
studies, which is the existence of a relatively small population to be studied. This limits 
the availability to perform a more detailed analysis and especially the possibility of 
performing tests to validate hypotheses with a robust statistic result. Another relevant 
limitation is the differences found between the profile of the respondents and the profile 
of all companies of the sector (the reasons for that were explored above).  
In terms of the need for further research, this study opens the door for a more detailed 
analysis on the internationalisation of the sector. Seeking to have a better knowledge of 
the process some subjects are proposed for further research: 
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• to analyse the financial data from the companies and compare it with the 
results from the study in order to verify the link between the perception of the 
managers towards the several markets and the real exporting performance;  
• to identify correlations between the internationalisation theories and the size 
of company, degree of internationalisation or type of marketed products; 
• to study the reasons why so many large companies have decided not to 
increase their internationalisation degree with foreign direct investment, 
namely the creation of manufacturing sites abroad; 
• to repeat the research, but limited to small and medium-sized enterprises and 
find if the strategies followed are different.  
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APPENDIX I - ECONOMIC ACTIVITY CODE & COMBINED NOMENCLATURE 
Economic activity code – detailing 
Section C – Manufacturing industry 
Division Group Class Subclass Definition 
21.  
 
Manufacturing of pharmaceutical products – base and finished products. 
211 2110 21100 Manufacturing of pharmaceutical products: base. 
212 2120 Manufacturing of pharmaceutical products: finished. 
  21201 Manufacturing of medicines 
  21202 Manufacturing of other pharmaceutical products 
Adapted from (INE, 2007) 
 
Combined nomenclature 
CN code Description 
3003 Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of two or 
more constituents which have been mixed together for therapeutic or prophylactic uses, 
not put up in measured doses or in forms or packings for retail sale: 
3003 10 00   - Containing penicillins or derivatives thereof, with a penicillanic acid structure, 
or streptomycins or their derivatives 
3003 20 00 - Other, containing antibiotics: 
- Other, containing hormones or other products of heading 2937 
3003 31 00 o Containing insulin 
3003 39 00 o Other  
 - Other, containing alkaloids or derivatives thereof:  
 
3003 41 00 o Containing ephedrine or its salts 
3003 42 00 o Containing pseudoephedrine (INN) or its salts 
3003 43 00 o Containing norephedrine or its salts 
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3003 49 00 o Other 
3003 60 00 - Other, containing antimalarial active principles described in Subheading Note 2 
to this Chapter 
3003 90 00 - Other 
3004 Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or 
unmixed products for therapeutic or prophylactic uses, put up in measured doses 
(including those in the form of transdermal administration systems) or in forms or 
packings for retail sale: 
3004 10 00 - Containing penicillins or derivatives thereof, with a penicillanic acid structure, 
or streptomycins or their derivatives 
3004 20 00 - Other, containing antibiotics 
- Other, containing hormones or other products of heading 2937: 
3004 31 00 o Containing insulin 
3004 32 00 o Containing corticosteroid hormones, their derivatives or structural 
analogues 
3004 39 00 o Other 
 - Other, containing alkaloids or derivatives thereof: 
3004 41 00 o Containing ephedrine or its salts 
3004 42 00 o Containing pseudoephedrine (INN) or its salts 
3004 43 00 o Containing norephedrine or its salts 
3004 49 00 o Other 
3004 50 00 - Other, containing vitamins or other products of heading 2936 
3004 60 00 - Other, containing antimalarial active principles described in Subheading Note 2 
to the Chapter 30 
3004 90 00 - Other 
 
Adapted from (European Comission, 2017) 
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APPENDIX II - WEB SURVEY QUESTIONS IN ENGLISH 
 
Q1 From a general perspective, what kind of international activities apply to your company? 
                    Instructions:  - You can choose more than one option. 
▢ Distribution (own brand) in foreign countries | ▢ Licensing out of your products/technologies in foreign 
countries  | ▢ Manufacturing sites located in foreign countries | ▢ Joint Venture with companies from 
foreign countries | ▢ Co-development of products | ▢ Sales office in a foreign country| ▢ Import 
of raw materials (including active pharmaceutical ingredients) | ▢ No international business activity 
Other  ________________________________________________ 
Skip To: Q8 If From a general perspective, what kind of international activities apply to your company?   Instru... = No 
international business activity 
 
Q2 From all the markets your company currently has international activities, please fulfil the table below for the 5 
countries you consider as the most important for your company.  Instructions:  - Please fulfil the 5 most important 
countries to your company from left (most important) to right (5th moslt important). - Please complete the country 
name in the box, and select the activities that you have on the market on the list below (you can choose more than one 
activity for each market). - In case you have activities in less than 5 countries, please answer for the countries where 








































Country 1  ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Country 2  ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Country 3  ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Country 4  ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Country 5  ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
 
Q3 For the 2 most important international markets for your company, please mark which activities you had in the below 
years.  Instructions: - You can choose more than one option for each market. - The country name was automatically 
fulfilled from the previous answer.                               - In case you have activities in less than 2 countries, please 
answer for the country where you have activity. 
 
 Country1: ${Q2/ChoiceTextEntryValue/1} Country2: ${Q2/ChoiceTextEntryValue/2} 
 2000 2005 2010 2015 2017 2000 2005 2010 2015 2017 
Distribution (own 
brand)  
▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 




▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Manufacturing site  ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
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Joint venture with 
local company  
▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Co-development of 
products  
▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Sales office  ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Import from this 
country  
▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Other   ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
 
Q4 For the below countries/regions, please indicate in which ones you have any international activity. And which is 
the main business model followed in those countries/regions:     Instructions: 
  - For all regions/countries, please select YES/NO - For all regions/countries you selected YES, please select the main 
activity from the dropdown list.  
 
Do you have international activities in this 
region/country 
IF YES, please chose 
the main model you 
associate with this region: 
 Yes No   
Portuguese speaking 
African countries  
▢ ▢ ▼ If yes, drop down 
Brazil  ▢ ▢ ▼ If yes, drop down 
Spain  ▢ ▢ ▼ If yes, drop down 
Middle East and Africa  ▢ ▢ ▼ If yes, drop down 
Europe and Australia ▢ ▢ ▼ If yes, drop down 
North America  ▢ ▢ ▼ If yes, drop down 
Latin America  ▢ ▢ ▼ If yes, drop down 
Asia  ▢ ▢ ▼ If yes, drop down 
Other  ▢ ▢ ▼ If yes, drop down 
▼Drop down options: Distribution (own brand), Licensing out, Manufacturing site, Joint venture, Sales office, Import 
from this country, Other, No activity, Co-development. 
 
Q5 Which of the following statements describes your company the best? 
Instructions:- Please select one of the two options 
▢ We concentrate our resources on carefully selected target countries. | ▢ Our purpose is to do business in as many 
countries as possible.  
 
Q6 Do you agree that the following influenced your decision to internationalise?  
Instructions: - Please select for each sentence if you agree or disagree (use the scale). - Please answer only regarding 
your decision to internationalise or not. 
 Strongly Agree Somewhat 
Neither 
agree nor 
Somewhat Disag Strongly 
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agree agree disagree  disagree ree disagree  
Successful experience from 
other companies in the 
internationalisation process 
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
To reduce the exposure to the 
national market  
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Explore new markets to grow  ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Governmental measures (inc. 
national or EU programs)  
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Contacts received from 
foreign companies 
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Reduction of the transaction 
costs (commissions, taxes, 
etc.)   
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Increase the lifecycle of 
established products in the 
current markets   
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Possibility of explore a 
superior competitive position 
of rival domestic companies  
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Take advantage of the location 
of the destination country  
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Avoid the knowledge to be 
shared with third parties 
(traders, agents, etc.)   
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Exhibition and networking 
events  
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
 
Q7 Which of the  following most influenced your decision about the destination of the international activities?  
Instructions:  - You can select more than one option (up to a maximum of 3) - Please select all situations that somehow 
affected your decision of the country of destination of your internationalisation (example, if you have decided to 
internationalise to Spain because there was another company that had a good experience there, please select "Successful 
experience from other companies in the same country of destination"). 
 
▢ Successful experience from other companies in the same country of destination  | ▢ Established network in the 
country of destination | ▢ Similar business culture and/or language in the country of destination| ▢ Country of 
destination belongs to the European Union | ▢ Market size of the country of destination | ▢ Regulatory and legal 
environment in the country of destination | ▢ International business activities in geographically close countries to the 
country of destination | ▢ Country of destination openness to international trade (with little barriers to entrance) | ▢ 
Exhibition and networking events | ▢ Access to finance (namely credit) in the destination country  | ▢ None of the 
above   | ▢ Other (please specify) ________________________________________________ 
 
Q8 In your opinion, how have the financial crisis (from 2008 – 2013) influenced your willing to 
internationalise? Instructions:                       - Please select one of the three options. 
▢ Increased my will to internationalise   | ▢ Didn't affected at all my will to internationalise  | ▢ Reduced my will to 
internationalise 
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Q9 In your opinion, what will happen to the importance of international business activity for your enterprise within the 
next 3 years? Instructions:                       - Please select one of the five options. 
▢ Increases a lot | ▢ Increases somewhat | ▢ Stays the same  | ▢ Decreases somewhat  | ▢ Decreases a lot 
 
Q10 What is your perception about the impact of the international business activities to your 
company?  Instructions:                       - Please select one of the 6 options. 
▢ Very positive  | ▢ Positive  | ▢ Neutral  | ▢ Negative  | ▢ Very negative  | ▢ The company does not have any 
experience with internationalisation  
 
Q11 Does the senior management of your company has international experience?  
                  Instructions:  - You can select more than one option. 
▢ No international experience | ▢ International working experience abroad | ▢ Work experience in international 
companies in Portugal | ▢ Studied abroad | ▢ Other international experience. Please refer what:  _____________ 
 
Q12 What is the main core business of your company? Instructions: - You can select more than one option (up to a 
maximum of 3) 
▢ Innovative medicines (including value added medicines)  | ▢ Generic medicines  | ▢ Over the counter medicines | 
▢ Cosmetics | ▢ Active Pharmaceutical Ingredients or raw materials | ▢ Services (including clinical trials, analytical 
and/or R&D) | ▢ Fast moving consumer goods (such as food supplements, nutraceuticals, medical devices and others)  
| ▢ Medicinal Gases  | ▢ Veterinary Products  | ▢ Other, please refer which _________________________________ 
 
Q13 How many employees you company has?  Instructions:   - You can select just one option.   - In case of a group of 
companies, please refer to the whole group.   
▢ 0 to 25 | ▢ 26 to 50 | ▢ 51 to 100 | ▢ 101 to 250 | ▢ 251 to 500 | ▢ More than 500 
 
Q14 What is the annual turnover of your company? Instructions: - You can select just one option.  - In case of a group 
of companies, please refer to the whole group. 
▢ < 1 Million €  | ▢ 1 to 5 Million €  | ▢ 6 to 10 Million €  | ▢ 11 to 25 Million €  | ▢ 26 to 50 Million €  | ▢ 51 to 
100 Million € | ▢ > 100 Million € 
 
Q15 What percentage of the annual turnover referred on the previous question comes from international sales? 
Instructions: - You can select just one option.                       - In case of a group of companies, please refer to the whole 
group. 
▢ 0%   | ▢ 0% to 10%   | ▢ 11% to 25%  | ▢ 26% to 50%   | ▢ 51% to 75%   | ▢ 76% to 100   
 
Q16 Is your company part of a multinational group with headquarters outside Portugal? 
▢ Yes    | ▢ No  | ▢ I don't know or I don't want to answer    
 
Q17 Here are a few background questions regarding you or the company you represent.  
In which year your company started to have international business activity? __________________ 
Year of foundation of your company: ________________________________________________ 
Your position within the company  ______________________________________________ 
 
Q18 Here are a few background questions regarding you or the company you represent. Please note that the below 
questions won't be used for statistic analysis, the only purpose of those are to validate the data, so we appreciate all 
information you can provide. ALL answers will always remain anonymous.   
Name of the company (optional): ________________________________________________ 
Your name (optional) ________________________________________________ 
 
Q19 Would you be interested in receiving the conclusions of this survey? If so, please provide your email address. 
________________________________________________________ 
End of Survey.  
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APPENDIX III - WEB SURVEY QUESTIONS IN PORTUGUESE 
Q1 De uma maneira geral, qual ou quais das➘seguintes atividades se aplicam à sua empresa a nível internacional? 
▢ Distribuição das marcas próprias no estrangeiro | ▢ Licenciamento de produtos e/ou tecnologias 
para outros países  | ▢ Fábrica de produção em países estrangeiros | ▢ Joint Venture com empresas 
estrangeiras  | ▢ Co-desenvolvimento de produtos | ▢ Força de vendas (com escritórios e trabalhadores) no 
estrangeir | ▢ Importação de matérias-primas (incluíndo princípios ativos, API) | ▢ Não temos actividades 
internacionais | ▢ Outras ________________________________________________ 
Skip To: Q8 If From a general perspective, what kind of international activities apply to your company?   Instru... = 
No international business activity 
 
Q2 Considerando todos os países onde a empresa tenha atividade internacional, preencha a tabela seguinte com 
informação relativamente aos 5 países que considera mais importantes para a sua empresa. Instruções de preenchimento 
- Por favor coloque os 5 países mais importantes para a sua empresa da esquerda (mais importante) para a direita (o 
quinto mais importante). - Por favor escreva o nome do país na caixa de texto e selecione as actividades que tem naquele 
país (pode selecionar mais de uma opção). - No caso de ter atividade em menos de 5➘países, por favor responda para 









































País 1  ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
País 2  ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
País 3  ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
País 4  ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
 
Q3 Para os dois países mais importantes para a sua empresa, por favor indique quais das seguintes atividades tinha em 
cada um dos anos. - Pode selecionar mais de uma opção para cada país. - O nome do país é automaticamente preenchido 
de acordo com a sua resposta à questão anterior. No caso de não ter atividade em 2 países, por favor responda para o 
país onde tem atividade. 
 Páis 1: ${Q2/ChoiceTextEntryValue/1} País 2: ${Q2/ChoiceTextEntryValue/2} 









▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Fábrica de 
produção 




▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Co-
desenvolviment
o de produtos 
▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
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▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Importação  ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Outros   ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
 
Q4 Para cada uma das regiões (em baixo), por favor indique em quais tem algum tipo de actividade internacional e 
qual é o principal tipo de atividade que tem. Instruções de preenchimento: - Para todos os países/regiões por favor 
selecione SIM/NÃO; - Para todos os países/regiões em que selecionou SIM, por favor selecione da lista qual o tipo de 
atividade mais relevante. 
 Tem algum tipo de atividade na região/país? 
Se SIM, por favor selecione o 
modelo que associa a esta região: 
 Sim Não  
PALOPS ▢ ▢ ▼ If “sim”, drop down 
Brasil  ▢ ▢ ▼ If “sim”, drop down 
Espanha ▢ ▢ ▼ If “sim”, drop down 
Médio Oriente e África ▢ ▢ ▼ If “sim”, drop down 
Europa e Austrália ▢ ▢ ▼ If “sim”, drop down 
América do Norte ▢ ▢ ▼ If “sim”, drop down 
América Latina ▢ ▢ ▼ If “sim”, drop down 
Ásia ▢ ▢ ▼ If “sim”, drop down 
Outras  ▢ ▢ ▼ If “sim”, drop down 
▼Drop down options: Distribuição (marca própria), Licenciamento, Fábrica de produção, Joint Venture, Estrutura de 
vendas, Importação, Outro, Qual?, Sem atividade, Co-desenvolvimento de produtos 
 
Q5 Qual das seguintes frase melhor descreve o comportamento da sua empresa? Instruções de preenchimento: - Por 
favor escolha uma das duas opções disponíveis: 
▢ Concentramos os nossos esforços em alguns países selecionados. 
▢ Tentamos encontrar possibilidades para expansão do nosso negócio em tantos países quanto possível. 
 
Q6 Considera que as seguintes situações influenciaram a sua decisão de internacionalizar? Instruções de 
preenchimento: - Por favor selecione para cada uma das frases se concorda ou discorda (usando a escala); - Por favor 



















Sucesso de outras 
empresas no processo 
de internacionalização 
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Reduzir a exposição 
ao mercado nacional 
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Explorar novos 
mercados para crescer 
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Medidas ▢ ▢ ▢ ▢ ▢ ▢ ▢ 
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de apoio nacionais e 
Europeus) 
Contacto recebido por 
parte de empresas 
estrangeiras 
▢ ▢ ▢ ▢ ▢ ▢ ▢ 




▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Aumentar o ciclo de 
vida de produtos 
estabelecidos em 
novos mercados 
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Possibilidade de tirar 




▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Tirar vantagem da 
localização geográfica 
do país 
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Evitar partilha de 
conhecimento (com 
traders, agentes, etc). 
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Feiras e eventos de 
networking 
▢ ▢ ▢ ▢ ▢ ▢ ▢ 
Q7 Quais das seguintes situações mais influenciaram a sua decisão sobre o destino para internacionalização da sua 
empresa? Instruções de preenchimento: - Pode selecionar mais de uma opção (até um máximo de 3). Por favor 
selecione todas as situações que de alguma maneira influenciaram a sua decisão sobre a escolha do país de destino para 
internacionalização da sua empresa (exemplo, se decidiu internacionalizar para Espanha porque uma outra empresa 
teve uma boa experiência lá, por favor selecione “Sucesso de outras empresas no mesmo país de destino”). 
▢ Sucesso de outras empresas no mesmo país de destino | ▢ Contactos existentes no país de destino | ▢ Cultura de 
negócio e/ou linguagem semelhante no país de destino | ▢ O facto do país de destino pertencer à União Europeia | ▢ 
Dimensão do mercado do país de destino | ▢ O ambiente regulamentar e legal do país de destino | ▢ Atividades em 
países geograficamente próximos ao país de destino | ▢ A abertura do país de destino a negócios internacionais (com 
baixas barreiras à entrada) | ▢ Feiras e eventos de networking | ▢ Acesso a financiamento (nomeadamente crédito) no 
país de destino | ▢ Nenhuma das anteriores | ▢ Outra (por favor diga qual/quais)_ __________________________ 
 
Q8 Na sua opinião, de que forma a crise financeira (2008 - 2013) influenciou a sua vontade para internacionalizar? 
Instruções de preenchimento: - Por favor escolha uma das 3 opções possíveis. 
▢ Aumentou a minha vontade para internacionalizar | ▢ Não afetou a minha vontade para internacionalizar | ▢ Reduziu 
a minha vontade para internacionalizar 
 
Q9 Na sua opinião, como vai variar a importância do negócio internacional para a sua empresa nos próximos 3 anos?  
Instruções de preenchimento: - Por➘favor escolha uma das 5 opções possíveis. 
▢ Vai aumentar muito | ▢ Vai aumentar | ▢ Vai manter-se igual  | ▢ Vai diminuir  | ▢ Vai diminuir muito 
 
Q10 Como classifica o impacto que as atividades de negócio internacional tiveram para a sua empresa? Instruções de 
preenchimento: Por favor escolha uma das 6 opções possíveis. 
▢ Muito positivo | ▢ Positivo | ▢ Neutro | ▢ Negativo | ▢ Muito negativo | ▢ A empresa não tem atividades de 
negócio internacional 
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Q11 Os quadros superiores da sua empresa têm algum tipo de experiência internacional? Instruções de preenchimento: 
- Pode selecionar mais de uma opção. 
▢ Não têm experiência internacional | ▢ Têm experiência de trabalho internacional no estrangeiro  | ▢ Têm experiência 
de trabalho em empresas internacionais em Portugal | ▢ Estudaram no estrangeiro | ▢ Outra experiência internacional. 
Por favor refira qual:  ________________________________________________ 
 
Q12 Qual considera ser o principal "core business" da empresa? Instruções de preenchimento – Pode selecionar mais 
de uma opção (até um máximo de 3): 
▢ Medicamentos inovadores (incluindo value added medicines, VAM) | ▢ Medicamentos genéricos | ▢ Produtos de 
OTC (MNSRM e MNSRM-EF) | ▢ Cosméticos | ▢ Princípio ativo e matérias-primas | ▢ Serviços (incluíndo ensaios 
clínicos, analíticos e/ou I&D). | ▢ Produtos de grande consumo (incluíndo suplementos alimentares, nutracêuticos, 
dispositivos médicos e outros) | ▢ Outros, por favor refira quais. | ▢ Gases Medicinais | ▢ Produtos Veterinários | ▢ 
Outros, por favor refira quais ________________________________________________ 
 
Q13 Quantos funcionários tem a sua empresa? Instruções de preenchimento: Apenas pode selecionar uma opção. - No 
caso de se tratar de um grupo, por favor refira-se ao total do grupo. 
▢ 0 a 25 | ▢ 26 a 50 | ▢ 51 a 100 | ▢ 101 a 250 | ▢ 251 a 500 | ▢ Mais de  than 500 
 
Q14 Qual é a faturação anual da sua empresa? Instruções de preenchimento - Apenas pode selecionar uma opção. - No 
caso de se tratar de um grupo, por favour refira-se ao total do grupo. 
▢ < de 1 milhão €  | ▢ Entre 1 e 5 milhões €  | ▢ Entre 6 e 10 milhões €  | ▢ Entre 11 e 25 milhões €  | ▢ Entre 26 e 
50 milhões €  | ▢ Entre 51 e 100 milhões € | ▢ > de 100 milhões € 
 
Q15 Que percentagem da faturação que referiu no ponto anterior tem origem no negócio internacional Instruções de 
preenchimento - Apenas pode selecionar uma opção. - No caso de se tratar de um grupo, por favor refira-se ao total do 
grupo. 
▢ 0% | ▢ 0% a 10%  | ▢ 11% a 25%  | ▢ 26% a 50%   | ▢ 51% a 75%   | ▢ 76% a 100  
 
Q16 A sua empresa faz parte de um grupo multinacional com sede fora de Portugal? 
▢ Sim  | ▢ Não | ▢ Não sei ou prefiro não responder 
 
Q17 Por último, por favor responda relativamente à sua empresa e a si: 
Em que ano a empresa iniciou as atividades de negócio internacional?__________________ 
Em que ano a empresa foi fundada? ________________________________________________ 
O seu cargo na empresa  ______________________________________________ 
 
Q18 Por último, gostaríamos de pedir informação sobre a sua empresa. Esta informação não será usada para tratamento 
estatístico, tem como único objetivo permitir a validação dos dados. TODA a informação permanecerá sempre anónima. 
Nome da empresa (opcional):________________________________________________ 
O seu nome (opcional): ________________________________________________ 
 




End of Survey. 
 
